Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence
- Resource Type
- Article
- Source
- In
Urologic Oncology: Seminars and Original Investigations November 2013 31(8):1800-1805 - Subject
- Language
- ISSN
- 1078-1439